AlphaQuest’s Astria Therapeutics ATXS Stock Holding History

AlphaQuest’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,782	Closed	-$337K	–	191
2025 Q4	$337K	Sell	25,782 -38,826	-60%	-$464K	0.02%	1126
2025 Q3	$470K	Buy	64,608 +50,392	+354%	+$341K	0.03%	831
2025 Q2	$76.2K	Hold	14,216	–	–	0.01%	1513
2025 Q1	$75.9K	Buy	14,216 +7,139	+101%	+$49.9K	0.01%	1409
2024 Q4	$63.3K	Sell	7,077 -1,927	-21%	-$20.5K	0.01%	1234
2024 Q3	$99.1K	Buy	9,004 +5,798	+181%	+$64.5K	0.01%	1286
2024 Q2	$29.2K	Buy	3,206 +3,112	+3,311%	+$30.4K	﹤0.01%	1246
2024 Q1	$1.32K	Buy	+94	New	+$1.17K	﹤0.01%	1218

AlphaQuest's ATXS Position: Q1 2026 in Review

AlphaQuest sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 25,782 shares — an estimated $337K sold.

AlphaQuest first reported a position in ATXS in Q1 2024 and held it in 8 quarters. The position peaked at $470K in Q3 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

AlphaQuest reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
AlphaQuest sold 25,782 Astria Therapeutics shares in Q1 2026, an estimated $337K.
AlphaQuest first reported a position in Astria Therapeutics in Q1 2024 and held it in 8 quarters.
AlphaQuest's Astria Therapeutics position peaked at $470K in Q3 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.